Eric Benevich compensation by year
NEUROCRINE BIOSCIENCES Summary Compensation Table · all 5 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Salary | $467,200 | $432,600 | $467,200 | $636,848 | $668,690 |
| Bonus | $280,320 | $205,485 | $280,320 | $366,188 | $463,000 |
| Stock awards | $1,250,035 | $1,499,417 | $1,250,035 | $2,800,081 | $2,349,928 |
| Option awards | $3,750,345 | $1,496,335 | $3,750,345 | $2,449,932 | $2,349,995 |
| Non-equity incentive | $0 | $38,768 | $45,547 | $0 | $0 |
| Pension and deferred compensation | — | — | — | — | $0 |
| All other | $45,547 | $38,768 | $45,547 | $53,115 | $57,334 |
| Total | $5,793,447 | $3,672,605 | $5,793,447 | $6,306,164 | $5,888,947 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NEUROCRINE BIOSCIENCES INC DEF 14A filed April 15, 2026, accession 0000914475-26-000015, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 16,613 | $2,356,222 | — |
| RSU | 12,550 | $1,779,967 | — |
| PSU | 12,033 | $1,706,641 | — |
| RSU | 8,022 | $1,137,760 | — |
| RSU | 5,885 | $834,670 | — |
| RSU | 4,166 | $590,864 | — |
| RSU | 2,294 | $325,358 | — |
| Option | 15,103 | — | $103.52 |
| Option | 33,887 | — | $117.18 |
| Option | 1,302 | — | $79.02 |
| Option | 21,356 | — | $133.84 |
Per the Outstanding Equity Awards at Fiscal Year-End table in NEUROCRINE BIOSCIENCES INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
5 Form 4 lines since the FY2025 proxy (filed April 15, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-11 | Grant or award | — | 6,275 | $0.00 | 70,683 |
| 2026-09-11 | Tax withholding | — | 3,386 | $156.22 | 67,297 |
| 2026-09-09 | Exercise or conversion | 10b5-1 | 3,194 | $43.24 | 66,562 |
| 2026-09-09 | Exercise or conversion derivative | 10b5-1 | 3,194 | $0.00 | 0 |
| 2026-09-09 | Sale | 10b5-1 | 2,154 | $154.61 | 64,408 |
The 5 most recent of 5 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments NEUROCRINE BIOSCIENCES discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $1,604,856 | $9,926,503 | $54,504 | $12,083,524 |
| Resignation for good reason, no change in control | $1,069,904 | $2,103,526 | $36,336 | $3,707,427 |
| Disability | — | $9,926,503 | — | $10,022,950 |
| Involuntary termination without cause | $1,069,904 | $2,103,526 | $36,336 | $3,707,427 |
| Change in control and resignation for good reason | $1,604,856 | $9,926,503 | $54,504 | $12,083,524 |
| Death | — | $9,926,503 | — | $10,022,950 |
Per the Potential Payments Upon Termination or Change in Control table in NEUROCRINE BIOSCIENCES INC's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
NEUROCRINE BIOSCIENCES’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Kyle Gano | Chief Executive Officer and Director | $13,448,935 |
| Sanjay Keswani | Chief Medical Officer | $9,007,803 |
| Jude Onyia | Chief Scientific Officer | $7,410,769 |
| Matthew Abernethy | Chief Financial Officer | $6,311,912 |
| Eiry Roberts | Strategic Advisor | $6,073,032 |
| Eric Benevich · this page | Chief Commercial Officer | $5,888,947 |
The full NEUROCRINE BIOSCIENCES compensation record
free company briefThis page is one person within NEUROCRINE BIOSCIENCES's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order NEUROCRINE BIOSCIENCES's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NEUROCRINE BIOSCIENCES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat